{"title":"米尔纳西普兰治疗纤维肌痛。","authors":"J Dempsey","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia.</p>","PeriodicalId":83756,"journal":{"name":"Issues in emerging health technologies","volume":" 114","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2008-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Milnacipran for fibromyalgia.\",\"authors\":\"J Dempsey\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia.</p>\",\"PeriodicalId\":83756,\"journal\":{\"name\":\"Issues in emerging health technologies\",\"volume\":\" 114\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2008-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Issues in emerging health technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Issues in emerging health technologies","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
(1) Milnacipran is an antidepressant that is under investigation for the treatment of fibromyalgia (a chronic pain disorder). (2) Preliminary evidence suggests that milnacipran may benefit some patients with fibromyalgia, but adverse effects may limit its use. (3) Complete results of phase 3 trials have not yet been published. Further studies are needed to evaluate the safety and efficacy of milnacipran, determine optimal dosing, confirm if beneficial effects are sustained, and clarify the drug's role relative to, and in conjunction with, other treatments for fibromyalgia.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
